Current status and challenges of model-informed drug discovery and development in China,Advanced Drug Delivery Reviews

当前位置： X-MOL 学术 › Adv. Drug Deliver. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Current status and challenges of model-informed drug discovery and development in China
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-10-09 , DOI: 10.1016/j.addr.2024.115459
Yuzhu Wang, Jia Ji, Ye Yao, Jing Nie, Fengbo Xie, Yehua Xie, Gailing Li

In the past decade, biopharmaceutical research and development in China has been notably boosted by government policies, regulatory initiatives and increasing investments in life sciences. With regulatory agency acting as a strong driver, model-informed drug development (MIDD) is transitioning rapidly from an academic pursuit to a critical component of innovative drug discovery and development within the country. In this article, we provided a cross-sectional summary on the current status of MIDD implementations across early and late-stage drug development in China, illustrated by case examples. We also shared insights into regulatory policy development and decision-making. Various modeling and simulation approaches were presented across a range of applications. Furthermore, the challenges and opportunities of MIDD in China were discussed and compared with other regions where these practices have a more established history. Through this analysis, we highlighted the potential of MIDD to enhance drug development efficiency and effectiveness in China’s evolving pharmaceutical landscape.

更新日期：2024-10-09

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南